By Denny Jacob
Lixte Biotechnology Holdings on Monday said a collaboration with the Netherlands Cancer Institute showed that inhibition of an enzyme in colon cancer cells using the company’s lead clinical compound, LB-100, leads to changes in the way the cancer cells process their mRNAs.
Shares rose 25% to $6.77 in early trading, putting the stock on pace for its largest percentage increase in a little over five months. Trading was paused for volatility four times and resumed trading at 10:55 a.m. ET.
The clinical-stage pharmaceutical company said the findings show that cancer cells are predicted to produce a significant number of aberrant proteins that can be recognized by the immune system, a mechanism which would potentially allow LB-100 to immunologically target cancer cells.
Write to Denny Jacob at [email protected]
Read the full article here
